ArcDia International Ltd.
ArcDia’s mariAST® is the most promising platform to tackle antibiotic resistance, a growing concern that directly causes 23,000 deaths every year in the US alone, and can soon make many routine operations too risky to perform.
Since 2011, ArcDia’s mariPOC® has been in use for rapid detection of respiratory infectious diseases. It is a near-patient technology with ease-of-use, cost-efficiency, high performance and accuracy. mariPOC® test system is IVD CE marked for respiratory tract infections, tonsillitis and gastroenteritis testing.
The mariAST® and mariPOC® platforms are based on the proprietary ArcDia™ TPX detection technology (Nature Biotechnology 2000). The TPX technology allows multianalyte rapid testing with fully automated and random-access test system.
Company history in infectious disease diagnostics:
- 1998-2003 Fundamental inventions of the TPX technology were made in the Laboratory of Biophysics (University of Turku, Finland) led by professor Erkki Soini.
- 2000 The TPX detection technique was published in Nature Biotechnology.
- 2005-2009 The applicability of TPX detection technique for rapid in vitro testing of infectious diseases was demostrated in academic projects in Turku University.
- 2008 ArcDia International Oy Ltd. was founded. mariPOC® product development project began.
- 2011 mariPOC® product was IVD CE marked and was introduced to the market.
- 2013 ArcDia received the ISO 13485 certificate.
- 2014 ArcDia Receives Frost & Sullivan Award for Point-of-Care Product Leadership.
- 2014 ArcDia moves in bigger permises in Turku Science Park area.
- 2015-2016 ArcDia releases new products: mariPOC®+ software mode, mariPOC® Gastro test panel and world’s first bocavirus antigen test
- 2017 ArcDia launches a new product: mariPOC®Quick StrepA test
- 2018 New product: mariPOC®Quick Flu/RSV test